50-70岁患者二尖瓣置换术中选择生物瓣或机械瓣的倾向性调整分析
这项多中心回顾性分析纳入2005年至2018年以色列4个医疗中心50-70岁行二尖瓣置换术的796例患者,其中机械瓣539例(67.8%)、生物瓣257例(32.2%)。
要点
- 65-70岁年龄组中,生物瓣与机械瓣的结局相似。
核心结论
- 在50-70岁患者中,年龄与机械瓣或生物瓣的结局存在交互作用:65岁以下患者使用机械瓣获得死亡获益,而65-70岁组结局相似。
- 这一结果支持当前指南推荐在65岁以下患者中使用机械瓣。
研究设计与样本
- 多中心回顾性分析,纳入2005年至2018年以色列4个医疗中心50-70岁行二尖瓣置换术的患者。
- 共796例纳入分析,其中机械瓣539例(67.8%),生物瓣257例(32.2%)。
- 使用倾向性调整分析控制组间差异,主要终点为全因死亡,次要终点包括再手术、脑血管意外和出血。
主要发现
- 研究期间共实施2125例二尖瓣置换术,796例符合纳入标准,平均年龄61.0±5.4岁。
- 次要终点在生物瓣与机械瓣之间也无差异。
- 研究期间再手术是死亡的强预测因素(72.2%)。
临床怎么用
- 原文结论支持当前指南推荐在65岁以下患者中使用机械瓣。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The choice of a bioprosthetic valve (BV) over a mechanical valve (MV) in middle-aged adults in the mitral position is still under debate. Each valve type has benefits and drawbacks. We examined the mid-term survival of patients aged 50-70 years after BV versus MV mitral valve replacement (MVR). METHODS: We conducted a multicentre, retrospective analysis of patients aged 50-70 years undergoing MVR from 2005 to December 2018 in 4 medical centres in Israel. To control for between-group differences, we used propensity-adjusted analysis. The primary end point was all-cause mortality. Secondary end points included reoperation, cerebrovascular accident and bleeding. RESULTS: During the study period, 2125 MVR procedures were performed. Of these, 796 were eligible for inclusion [539 (67.8%) MV replacement and 257 (32.2%) BV]. The mean age was 61.0 ± 5.4. There were 287 deaths during 4890 person-years of follow-up. The adjusted hazard ratio was (1.13 [0.85-1.49], P = 0.672). There was also no difference in the secondary end points. Subgroup analysis of patients aged 50-64 years showed a higher risk of mortality with BV (hazard ratio = 1.50 [1.07-2.1], P = 0.018). Reoperation was a strong predictor of mortality during the study period (72.2%). CONCLUSIONS: In patients aged 50-70 years, we found an interaction between age and MV or BV outcomes-those younger than 65 years gained a mortality advantage with MV, while outcomes were similar in the 65-70 age group. this supports the current guidelines recommending using MV in patients <65 years of age.
引用
- Leviner DB, Zafrir B, Saliba W, et al. Biological or mechanical mitral valve replacement in patients 50-70 years of age-a propensity-adjusted analysis. Eur J Cardiothorac Surg. 2022. PMID: 35138362. doi:10.1093/ejcts/ezac073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。